Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 532321 | NSE Symbol : ZYDUSLIFE | ISIN : INE010B01027 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
09-May-2025	20-May-2025	Final Dividend	Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2025 inter alia to consider and approve audited financial results for the quarter / year ended on March 31 2025 and to recommend final dividend for the financial year ended on March 31 2025. Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended March 31, 2025 The Board also recommended final dividend of Rs. 11/- (@1100%) per equity share of Re. 1/- each, subject to approval of the shareholders at the ensuing Annual General Meeting scheduled to be held on August 12, 2025. (As Per BSE Announcement Dated on 20.05.2025)
11-Mar-2025	11-Mar-2025	Acquisitions	Acquisition of shares of Amplitude Surgical SA, France, a listed entity
21-Jan-2025	05-Feb-2025	Quarterly Results	Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2025 inter alia to consider and approve unaudited financial results of the Company for the quarter / nine months ended on December 31 2024. Unaudited financial results for the quarter / nine months ended on December 31, 2024 (As Per BSE Announcement Dated on: 05/02/2025)
27-Dec-2024	27-Dec-2024	Acquisitions	Update on acquisition of a business
30-Oct-2024	12-Nov-2024	Quarterly Results	Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve unaudited financial results for the quarter and half year ended on September 30 2024. Unaudited financial results for the quarter and half year ended on September 30, 2024 Unaudited financial results for the quarter and half year ended on September 30, 2024 (As Per BSE Announcement Dated on 12.11.2024)
18-Jul-2024	09-Aug-2024	Quarterly Results	Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2024 inter alia to consider and approve unaudited financial results for the quarter ended on June 30 2024. Unaudited Financial results for the quarter ended June 30, 2024 (As Per BSE Announcement dated on 09.08.2024)
09-May-2024	17-May-2024	Accounts	Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/05/2024 inter alia to consider and approve audited financial results for the quarter and year ended on March 31 2024 Final dividend The Board of Directors at their meeting held today have recommended final dividend of Rs.3.00/- (@300%) per equity share of Re. 1/- each, subject to approval of the shareholders at the ensuing Annual General Meeting scheduled to be held on August 9, 2024 Appointment of Independent Director (As Per BSE Announcement Dated on 17.05.2024)
29-Jan-2024	09-Feb-2024	Quarterly Results	Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2024 inter alia to consider and approve Unaudited Financial Results for the quarter / nine months ended on December 31 2023. Buyback of shares Buyback of shares Record date of buyback: February 23, 2024 Unaudited financial results for the quarter and nine months ended on December 31, 2023 Buyback of shares (As Per BSE Announcement Dated on 09.02.2024) Newspaper cutting with regard to publication of extracts of unaudited financial results for the quarter / nine months ended on December 31, 2023 in Financial Express on February 10, 2024. (As Per BSE Announcement Dated on 10.02.2024)
30-Oct-2023	07-Nov-2023	Quarterly Results	Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2023 inter alia to consider and approve the unaudited financial results for the quarter / half year ended on September 30 2023. Unaudited Financial Results for the quarter / half year ended on September 30, 2023 Unaudited Financial Results for the quarter / half year ended on September 30, 2023 (As Per BSE Announcement Dated on 07.11.2023)
31-Jul-2023	11-Aug-2023	Quarterly Results	Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2023 inter alia to consider and approve the unaudited financial results for the quarter ended on June 30 2023. Unaudited Financial Results for the quarter ended on June 30, 2023 Unaudited Financial Results for the quarter ended on June 30, 2023 (As Per BSE Announcement Dated on 11.08.2023)
12-May-2023	18-May-2023	Accounts	Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/05/2023 inter alia to consider and approve apart from other agenda items approval of audited financial results for the quarter / year ended on March 31 2023 and to recommend final dividend for the financial year ended on March 31 2023. Outcome of Board meeting Re-appointment of Independent Director of the Company (As per BSE Announcement Dated on 18/05/2023)
23-Jan-2023	03-Feb-2023	Quarterly Results	Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2023 inter alia to consider and approve unaudited financial results for the quarter / nine months ended on December 31 2022. The Board of Directors at their meeting held today i.e. February 3, 2023, based on the recommendations of Audit Committee, approved the Unaudited Financial Results for the quarter / nine months ended on December 31, 2022. (As per BSE Announcement Dated on 03/02/2023)
29-Nov-2022	29-Nov-2022	Change in Directors	Appointment of two Independent Directors
31-Oct-2022	11-Nov-2022	Quarterly Results	Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2022 inter alia to consider and approve approval of unaudited financial results for the quarter / half year ended on September 30 2022. The Board of Directors at their meeting held today i.e. November 11, 2022, based on the recommendations of Audit Committee, approved the Unaudited Financial Results for the quarter / half year ended on September 30, 2022. (As Per BSE Announcement dated on 11.11.2022)
03-Aug-2022	10-Aug-2022	Quarterly Results	Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2022 inter alia to consider and approve unaudited financial results for the quarter ended on June 30 2022 Approval of the unaudited financial results for the quarter ended on June 30, 2022 (As Per BSE Announcement dated on 10.08.2022)

1 2

LOGIN HERE

Zydus Lifesciences Ltd

Board Meeting